NCT03313778
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03313778
Title Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)
Acronym KEYNOTE-603
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors ModernaTX, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | AUS

Facility Status City State Zip Country Details
The George Washington Cancer Center Washington D.C. District of Columbia 20037 United States Details
Orlando Health Cancer Institute Orlando Florida 32806 United States Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
H Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612-9416 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
NYU Langone Medical Center New York New York 10016 United States Details
The Cleveland Clinic Foundation Cleveland Ohio 44195-0001 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15219 United States Details
Westmead Hospital-Cnr Hawkesbury and Darcy Road Westmead New South Wales Australia Details
One Clinical Research Perth Perth Western Australia Australia Details
National Cancer Center East Chiba Japan Details
Kindai University Hospital Osaka Japan Details
National Cancer Center Hospital Tokyo Japan Details
The Cancer Institute Hospital of Japanese Foundation For Cancer Research Tokyo Japan Details
NHS Tayside Dundee Scotland United Kingdom Details
Royal Mardsen London London United Kingdom Details
Royal Mardsen Sutton Sutton United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field